New stem cell therapy shows 'promising' results for treating hair loss in preclinical trials
Researchers at the San Carlos Clinical Hospital in Madrid may have targeted a potential solution for hair loss.
A recent study analyzed the effect of injecting mice's skin with stem cells from human fat — "adipose-derived stem cells (ASCs)" — as a means of treating androgenetic alopecia (AGA), more commonly known as male- or female-pattern hair loss.
The team found that male mice achieved the best hair regrowth after three weeks when they received low-dose ASCs, combined with an energy-boosting molecule called adenosine triphosphate (ATP).
Hairstylists And Medical Expert Confirm Temporary Hair Loss Affecting Ozempic Users
Low-dose and high-dose ASC treatments along with ATP led to no hair regrowth improvement in females, but medium-dose ASC plus ATP led to greater regrowth.
The researchers concluded that hair regrowth was improved in "all experimental groups" where male mice received stem cell solutions supplemented with ATP.
Read On The Fox News App
The findings were published in the journal Stem Cell Research & Therapy.
Lead study author Dr. Eduardo López Bran — dermatologist and professor at The Complutense University of Madrid — shared his expectations for the study in an interview with Fox News Digital.
This Daily Beauty Routine Could Be Ruining Your Hair, Experts Warn
"We expected good results, but not such a high level of success," he said. "We're talking about a very high degree of hair regrowth in both male and female mice."
With appropriate doses, the researchers achieved "very high percentages" of hair regrowth, noting that 100% of the male mice and up to 90% of the female mice regrew hair.
"These results demonstrate that advanced therapies may represent a new therapeutic approach for many diseases for which no effective treatments are currently available," Bran went on.
"Achieving such promising results in the preclinical phase with a completely novel approach to androgenetic alopecia — one that avoids chronic treatment and is also safe — is a significant scientific milestone."
The main limitation of the study was the thinness of mouse skin, Bran noted, which "posed a challenge in administering the therapy."
"This required the development of protocols to minimize experimental variability, and will be a key factor when studies in humans begin," he said.
These new findings should be "interpreted with caution and scientific rigor," Bran cautioned.
"Although the results in mice represent significant progress, it is also true that it is essential to wait for clinical benefits in humans to be confirmed."
Click Here To Sign Up For Our Health Newsletter
The researcher encouraged those with androgenetic alopecia to continue consulting with their dermatologists and to follow prescribed treatments as research develops.
"It is important to remain hopeful. Research advances are pointing toward possible solutions that, in the future, may offer long-lasting results without the need for continuous treatment to maintain benefits," Bran added.
Looking ahead to human clinical trials, researchers are "actively working" on confirming safety for men and women between 18 and 50 years old with moderate androgenetic alopecia, the researcher noted.
"If everything progresses as expected, the most optimistic timeline points to the treatment becoming available in approximately five years," he said.
In a separate interview with Fox News Digital, Dr. Brendan Camp, M.D., a New York-based dermatologist who was not involved in the study, commented on the potential for this method.
"While not commercially available, this study suggests that injection of stem cells supplemented with ATP into scalp skin could potentially encourage hair regrowth in individuals with androgenetic alopecia," he reiterated.
For more Health articles, visit www.foxnews.com/health.
"This study is small, and more research is needed on this method as a potential treatment option for androgenetic alopecia."
Until then, Camp encourages people to focus on currently available and "well-studied" treatments to address hair loss, and to visit a board-certified dermatologist for evaluation.Original article source: New stem cell therapy shows 'promising' results for treating hair loss in preclinical trials
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
43 minutes ago
- New York Times
Did Baby Talk Give Rise to Language?
If you've ever cooed at a baby, you have participated in a very special experience. Indeed, it's an all but unique one: Whereas humans constantly chatter to their infants, other apes hardly ever do so, a new study reveals. 'It's a new feature that has evolved and massively expanded in our species,' said Johanna Schick, a linguist at the University of Zurich and an author of the study. And that expansion, Dr. Schick and her colleagues argue, may have been crucial to the evolution of language. Other mammals can bark, meow, roar and hoot. But no other species can use a set of sounds to produce words, nor build sentences with those words to convey an infinite variety of meaning. To trace the origin of our gift of language, researchers often study apes, our closest living relatives. These studies hint that some of the ingredients of language had already evolved in the ancestors we share with living apes, which lived millions of years ago. Chimpanzees can make dozens of distinct calls, for example, which they can join into pairs to communicate new things. Building meaning from smaller units is what lets us create sentences from words. Humans and apes are similar in another way: Their babies need time to learn how to make sounds like adults. Scientists have done much more research into how human infants develop language than into how wild baby apes learn to make calls. One striking feature of humans is the way that adults speak to young children. Baby talk — known to scientists as infant-directed speech — often features repeated words, an exaggerated stress on syllables and a high, singsong tone. This distinctive pattern is very effective at grabbing the attention of young children — even when they're too young to understand the meaning of the words that adults are saying. It's possible that children pay attention to infant-directed speech because it helps them learn some of the basic features of language. Want all of The Times? Subscribe.
Medscape
2 hours ago
- Medscape
NICE Backs Leadless Pacemakers for Some Heart Patients
The National Institute for Health and Care Excellence (NICE) has provisionally recommended leadless cardiac pacemaker implantation for patients with bradyarrhythmias who require single-chamber pacing. In draft guidance, NICE said there was insufficient evidence to support their use for dual-chamber pacing outside of research settings. Benefits Over Traditional Pacemakers The recommendation is based on an evidence review involving over one million patients across multiple studies. These included a randomised controlled trial, four systematic reviews with meta-analyses, five registry studies, four prospective studies, and two retrospective studies. Leadless pacemakers were found to be effective at detecting abnormal heart rhythms, restoring normal pacing, and improving quality of life. Unlike conventional transvenous pacemakers (TVPs), they do not require a chest incision, reducing the risk of infection and other complications, the regulator noted. 'The evidence demonstrates that leadless pacemakers can effectively regulate heart rhythm while reducing the risk of complications associated with traditional pacemakers, particularly infections and lead-related issues,' said Dr Anastasia Chalkidou, HealthTech programme director at NICE. How Leadless Pacemakers Work Bradyarrhythmias, which affect around 1 in 1000 people are typically treated with TVPs. These devices consist of a subcutaneous pacemaker box and leads that connect to the heart. For single-chamber leadless pacemakers, the proximal end is attached to a deflectable delivery catheter system. It is usually inserted percutaneously through the femoral or jugular vein using an introducer sheath. It is then moved into the right atrium, through the tricuspid valve, and into the right ventricle. Dual-chamber systems, which are still under evaluation, involve placing two devices — one in the right atrium and another in the right ventricle — during a single procedure. NICE highlighted that TVPs are known to carry risks, including lead failure and generator-related complications. Leadless pacemaker implantation may be preferable for patients with a history of device infection, endocarditis, immunosuppression, limited vascular access, or high infection risk. Call for Further Research While the draft guidance supports leadless pacemakers for single-chamber pacing, NICE said that more evidence is needed before endorsing their wider use. This includes research on patient selection — such as age, comorbidities, and the underlying cause of bradyarrhythmia — as well as data on implantation sites and clinical outcomes. Long-term durability of leadless devices also remains an area for investigation. 'The incidence of bradyarrhythmias increases with age, making this guidance particularly relevant to our ageing population,' said Professor Tom Clutton-Brock, chair of NICE's interventional procedures advisory committee. The draft guidance is open for public consultation until 23 July 2025. The advisory committee will meet again on 11 September 2025 to review feedback and finalise recommendations.
Medscape
2 hours ago
- Medscape
Two ‘Spectacular' Studies & Other Movement Disorder Updates
This transcript has been edited for clarity. Dear colleagues, I'm Christoph Diener, from the Faculty of Medicine at the University of Duisburg-Essen. In this month's video, I would like to concentrate on movement disorders. We understand that biomarkers play a hugely important role in Parkinson's disease for identifying preclinical stages for differential diagnosis with multisystem atrophy and for the assessment of prognosis in people with manifest Parkinson's disease. Prodromal Parkinson's and Two Spectacular Studies There are a number of biomarkers, like alpha-synuclein in cerebral spinal fluid, serum, and skin biopsy, dopaminergic biomarkers, imaging, and neurofilaments. Although we have at present no disease-modifying therapy, there is a need to identify individuals in the prodromal stage of Parkinson's disease once these treatments become available. There is a study based on the Health Professionals Follow-Up Study with 51,000 people and surveys between 2012 and 2017. In this particular manuscript, 6000 men were identified without Parkinson's disease. They were followed for 3.5 years, and 103 participants developed manifest Parkinson's disease. Potential prodromal symptoms, such as constipation, hyposmia, and REM sleep disorders, were recorded. If three of these prodromal symptoms were present, the risk of developing Parkinson's disease in the next 3 years is increased by a factor of 23, and this shows how important it is to identify these prodromal symptoms early. There were two spectacular publications in Nature , with a potentially new therapeutic approach for Parkinson's disease with the implantation of dopaminergic progenitor cells or blood-derived potent stem cells in the striatum in Parkinson's disease bilaterally. One study in the United States with 12 patients, who also received immunosuppression, showed no serious adverse events and in particular no tumors, and an increase in 18Fluoro-DOPA uptake in the putamen in the high-dose group on PET. A second study in Japan with seven patients over 24 months showed no safety signals with clinical improvement in six patients and 18F-DOPA uptake increasing by approximately 45% on PET. Both studies clearly show that stem cells can survive once they are implanted into the striatum. However, the clinical application is questionable, given the invasive nature and the high cost of these procedures. GLP-1 Drugs Disappoint, and Subcutaneous Apomorphine My next topic is GLP-1 agonists. There are epidemiologic studies and preclinical models that suggest the GLP-1 agonists, which are used for the treatment of diabetes and obesity, may be also effective in the prevention of neurodegenerative diseases. However, a randomized, placebo-controlled study with 2 mg exenatide per week subcutaneously vs placebo in 215 patients on dopaminergic medications showed no difference in the condition of is really frustrating, but further studies with different drugs are currently ongoing. Continuous, subcutaneous apomorphine has long been used in Europe in patients with Parkinson's disease and serious fluctuations. There is an ongoing study in the United States with 85 patients over 52 weeks, which clearly showed that OFF times with continuous, subcutaneous apomorphine decrease over time with high patient dose of levodopa can also be reduced. Typical side effects include local reactions, nausea, and somnolence. I think this is an important treatment, particularly in patients who cannot receive deep-brain stimulation. Common problems associated with Parkinson's disease are falls and cognitive was a small study that investigated an acetylcholine M 1 receptor-positive allosteric modulator called TAK-071 in 74 patients with at least one fall in the past 12 months. This was a crossover study with placebo over 6 weeks each. Unfortunately, gait disorders and falls were not functions were slightly improved, but I think this does not justify the use of this drug in the near future in people with Parkinson's disease, falls, and cognitive impairment. Dear colleagues, ladies and gentlemen, a few studies in movement disorders. The most spectacular, I think, are the two studies published in Nature . I am Christoph Diener, from the Faculty of Medicine at the University of Duisburg-Essen. Thank you very much for listening and watching.
